Subtype
Adult-Type Diffuse Glioma
CI-CAN-00009389Explore in graph →
510 active trials2 approved drugs70 evidence items
- OncoTree
- ADIFG
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00009389Explore in graph →
Clinical trials
1,869 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (295)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03688178 | DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab(DERIVe) | active not recruiting | Phase 2 | 43 | Annick Desjardins, MDOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05736406 | A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 12 | Hemerion TherapeuticsINDUSTRY | 2 | May 22, 2026 |
| NCT07411690 | Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors(CSF-IMR) | recruiting | — | 200 | Medical University of WarsawOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT07604285 | A Phase 1/2 Study of Safety and Tolerability of MT-125 With Chemoradiation in Patients With Newly Diagnosed MGMT Methylated Glioblastoma(NOVA-GBM) | not yet recruiting | Phase 1 / Phase 2 | 36 | Myosin Therapeutics Inc.INDUSTRY | 1 | May 22, 2026 | clinicaltrials |
| NCT07413796 | Comparison of Skin Closure Techniques in Oncological Neurosurgical Procedures: Intradermal Running Suture Versus Transdermal Interrupted Sutures(NEURO-SUTURE) | recruiting | N/A | 382 | Medical University of WarsawOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05500612 | MRI Hypoxia Study for Glioblastoma Multiforme (GBM) Radiation Therapy(MANGO) | recruiting | — | 20 | University of SydneyOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT07590726 | PIRe 2.0: A Stepped-Care Model for Involving Relatives Across Sectors(PIRe) | not yet recruiting | N/A | 160 | Rigshospitalet, DenmarkOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT04003649 | IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | active not recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT04477200 | Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma | active not recruiting | Phase 1 | 68 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05281731 | Sonobiopsy for Noninvasive and Sensitive Detection of Glioblastoma | recruiting | N/A | 40 | Washington University School of MedicineOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07042620 | A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery | active not recruiting | N/A | 15 | SonoClear ASINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT02192359 | Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas | active not recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06136611 | Preoperative Preradiotherapy TTFields(PORTRAIT) | recruiting | N/A | 42 | The Christie NHS Foundation TrustOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT04015700 | Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 9 | Washington University School of MedicineOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07284069 | Senicapoc and Perampanel for Newly Diagnosed Glioblastoma(SENIPERA) | recruiting | Early Phase 1 | 36 | Aarhus University HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02331498 | Phase I/II Study of Pazopanib+ Temozolomide in Patients With Newly Diagnosed Glioblastoma Multiforme(PAZOGLIO) | active not recruiting | Phase 1 / Phase 2 | 51 | Centre Antoine LacassagneOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT04699773 | LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138) | recruiting | N/A | 32 | University of Maryland, BaltimoreOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07343986 | Study of Low-Intensity Focused Ultrasound in Combination With Immunotherapy in Newly Diagnosed Unmethylated Glioblastoma(BATs FUS) | recruiting | Phase 1 | 12 | University of VirginiaOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05629702 | ARISTOCRAT: Blinded Trial of Temozolomide +/- Cannabinoids(ARISTOCRAT) | recruiting | Phase 2 | 120 | University of BirminghamOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06649851 | G-CSF After Chemo-radiation in Patients With Glioblastoma | recruiting | Phase 2 | 60 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03491683 | INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) | active not recruiting | Phase 1 / Phase 2 | 52 | Inovio PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT05241392 | Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma | active not recruiting | Phase 1 | 30 | Beijing Tiantan HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05743595 | Neoantigen-based Personalized DNA Vaccine With Retifanlimab PD-1 Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma | active not recruiting | Phase 1 | 27 | Washington University School of MedicineOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05933265 | Study of LP-184 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 64 | Lantern Pharma Inc.INDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT06176066 | PH Sensitive MRI Based Resections of Glioblastoma | recruiting | Phase 1 | 18 | University of California, Los AngelesOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05190172 | PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas(PRO-GLIO) | recruiting | N/A | 225 | Oslo University HospitalOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | recruiting | Phase 1 | 9 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07365124 | MRinRT: Swansea University and SWWCC Collaboration Study.(MRinRT) | not yet recruiting | — | 165 | Swansea Bay University Health BoardOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07443176 | FCI-Glioblastoma Study | not yet recruiting | — | 18 | University of AberdeenOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07297212 | A Clinical Trial Testing the Safety of the Investigational Drug Pumitamig (BNT327) and How Well it Works in Patients With Recurrent Glioblastoma | recruiting | Phase 2 | 75 | BioNTech SEINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04922723 | Radiation/Temozolomide and Immunotherapy With Daratumumab to Improve Antitumor Efficacy in Glioblastoma(PRIDE) | active not recruiting | Phase 1 / Phase 2 | 16 | West Virginia UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06039709 | Sonodynamic Therapy in Patients With Recurrent GBM(GBM 001) | recruiting | Phase 1 | 11 | Shayan Moosa, MDOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07552233 | NK Cell Therapy for Malignant Solid Brain Tumors | recruiting | N/A | 27 | Peking University Third HospitalOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT07552467 | Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors | recruiting | — | 26 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT05565521 | UNITy-BasED MR-Linac Adaptive Simultaneous Integrated Hypofractionated Boost Trial for High Grade Glioma in the Elderly(UNITED2) | active not recruiting | Phase 2 | 55 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT07551336 | Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma | recruiting | Phase 1 | 36 | Beijing BiotechINDUSTRY | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03383978 | Intracranial Injection of NK-92/5.28.z Cells in Combination With Intravenous Ezabenlimab in Patients With Recurrent HER2-positive Glioblastoma(CAR2BRAIN) | recruiting | Phase 1 | 42 | Johann Wolfgang Goethe University HospitalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT03961971 | Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM | active not recruiting | Phase 1 | 16 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT07546669 | Efficacy of Zoster Vaccination in Glioblastoma Patients(STARGATE) | not yet recruiting | Phase 4 | 230 | University Hospital, EssenOTHER | 0 | Apr 23, 2026 | clinicaltrials |
| NCT05366179 | Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc | recruiting | Phase 1 | 36 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05917145 | ATM-Inhibitor WSD0628 in Combination With Radiation Therapy for Treatment of Recurrent High-Grade Glioma | recruiting | Phase 1 | 94 | Mayo ClinicOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT06336291 | A Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence(GLIOSTELLA) | active not recruiting | Phase 2 | 90 | Philogen S.p.A.INDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05969860 | At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | recruiting | Phase 2 | 220 | Mayo ClinicOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT07538128 | Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma | recruiting | Early Phase 1 | 10 | Huashan HospitalOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT02287428 | Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM | active not recruiting | Phase 1 | 56 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04656535 | AB154 Combined With AB122 for Recurrent Glioblastoma | active not recruiting | Early Phase 1 | 46 | Yale UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT06466031 | Application of FET-PET in Fusion With MRI in the Treatment of Glioblastoma Multiforme [TYR-GLIO](TYR-GLIO) | recruiting | N/A | 189 | Copernicus Memorial HospitalOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04762069 | A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme | active not recruiting | Phase 2 | 252 | CNS Pharmaceuticals, Inc.INDUSTRY | 5 | Apr 15, 2026 | clinicaltrials |
| NCT07532031 | APT-weighted and Diffusion MRI for Characterizing Tumor Infiltration in High-Grade Gliomas(APT-HGG) | not yet recruiting | — | 20 | IRCCS Ospedale San RaffaeleOTHER | 0 | Apr 15, 2026 | clinicaltrials |
| NCT06512311 | Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening(ATTRACT) | recruiting | N/A | 240 | Medical University of ViennaOTHER | 1 | Apr 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 22, 2026source: clinicaltrials